Previous 10 | Next 10 |
2024-03-05 13:34:43 ET More on Eyenovia Eyenovia: Racing Toward The Finish Line Upcoming FDA decision: Eyenovia’s (EYEN) APP13007 Seeking Alpha’s Quant Rating on Eyenovia Historical earnings data for Eyenovia Financial information for Ey...
2024-03-05 12:38:40 ET Gainers: Sunshine Biopharma ( SBFM ) +147% . Airship AI Holdings ( AISP ) +87% . Datasea ( DTSS ) +79% . Dave ( DAVE ) +58% . Apogee Therapeutics ( APGE ) +49% . Ocean Biomedical ( OCEA ) +50% ....
Approval based on nearly 9 out of 10 patients achieving complete absence of post-surgical pain and 6 out of 10 achieving total absence of inflammation within 15 days post-ocular surgery Eyenovia plans to launch in the U.S. as soon as this summer using its Mydcombi™ sales force pr...
2024-02-13 13:02:35 ET More on Eyenovia Seeking Alpha’s Quant Rating on Eyenovia Historical earnings data for Eyenovia Financial information for Eyenovia Read the full article on Seeking Alpha For further details see: FDA approves Eyenovia ...
Redwood City, California to complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophth...
MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007 Part of corporate strategy to expedite commercialization of advanced products using the Optejet device ...
2023-12-15 08:17:05 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips You know you want it. High-potential penny stocks that is. And I’m here to deliver. However, from an obligatory standpoint, I must warn you from the get-go: people tend to lose money...
2023-11-13 21:34:10 ET Eyenovia, Inc. (EYEN) Q3 2023 Earnings Conference Call November 13, 2023, 4:30 PM ET Company Participants Glenn Garmont - LifeSci Partners, IR Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Officer Bren Kern - Ch...
2023-11-13 16:21:26 ET More on Eyenovia Eyenovia: It Is Now Time To See Positive Results In Their Marketing Efforts Eyenovia to raise capital via ~$12M securities offering Seeking Alpha’s Quant Rating on Eyenovia Historical earnings data for Eyenovia ...
Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals Announced FDA approval of Coastline International as contract manufacturer for Mydcombi cartridge subassemblies and preparations for natio...
News, Short Squeeze, Breakout and More Instantly...
Collaboration to focus on the development of a formulation of Senju’s SJP-0035 for use with Eyenovia’s Optejet ® dispensing technology, following consultation with FDA Chronic dry eye estimated to be a $5 billion global addressable market NEW YORK, July 23, ...
Partnership co-promoting NovaBay’s Avenova ® Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia’s FDA-approved product MydCombi™ Preparing for Eyenovia's launch of clobetasol propionate ophthalmic suspension, ...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional investor and its current large...